Trial Profile
Evaluation of the efficacy and safety of AVANZ Phleum pratense in grass pollen-induced allergic rhinitis during controlled exposure in an environmental challenge chamber
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2017
Price :
$35
*
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis; Grass pollen hypersensitivity; Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors ALK-Abello
- 25 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 14 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
- 03 Jun 2014 New trial record